Sernova Corp. (PSH.F)
| Previous Close | 0.1543 |
| Open | 0.1707 |
| Bid | 0.0000 x 1000000 |
| Ask | 0.0000 x 1000000 |
| Day's Range | 0.1707 - 0.1707 |
| 52 Week Range | 0.1288 - 0.5530 |
| Volume | |
| Avg. Volume | 2,041 |
| Market Cap | 55.533M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | Sept 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Sernova Corp.
Announces today that David Paterson Ph.D. will join Sernova’s Board of Directors effective immediately. ...
GlobeNewswireSernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function
Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantationHistological data confirmation of healthy beta, alpha and delta cells secreting insulin, glucagon, and somatostatin in all Cell Pouch ChambersSernova’s Cell Pouch safely contains its therapeutic cells and provides full retrievability using conventional instruments and methodsPathology confirmed no evidence of detrimental fibrotic tissue associ
- GlobeNewswire
Sernova Corp. Announces Appointment of New Chief Executive Officer
LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company’s new Chief Executive Officer. James Parsons, on behalf of the Board of Dir
